Thomas Simmerer takes over sales at Carl Zeiss Meditec

Succeeds Ulrich Krauss as member of the management board with responsibility for sales

Thomas Simmerer has taken over as a member of the management board responsible for sales at Carl Zeiss Meditec in Germany. He succeeds Ulrich Krauss who has transferred to the management board of Carl Zeiss Vision International, a subsidiary of the Carl Zeiss Group.

‘I am looking forward to my new responsibilities and will maintain and expand the successful sales and service structure at Carl Zeiss Meditec in the respective markets,’ said Simmerer.

Simmerer has extensive experience in medical technology. He was in charge of the Microsurgery strategic business unit in Oberkochen from October 2008. Before joining the medical wing of Carl Zeiss, the mechanical engineer led the top-performing business unit, among others, of Dräger Medical in Lübeck from 1996 to 2008. Prior to this, he was responsible for different sales areas at Heraeus in Hanau.

You may also like

Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems

Nemera expands production capacity in Szczecin to strengthen leadership in GLP-1 drug market

Nemera, a global leader in the design, development and manufacturing of drug delivery device solutions, has  inaugurated a new production hall at its facility in Szczecin, Poland
Manufacturing

Aggreko launches report to demystify UK F-gas transition

As the UK’s transition away from F-gases ramps up, Aggreko has published a new report to provide clarity on the latest regulations and offer businesses guidance on the phase-down
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Subscribe now